Recent Advances in the Management of Adverse Events Associated with Lorlatinib

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288. doi:10.21037/tlcr.2016.06.07
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001. doi:10.1200/JCO.2012.46.9270
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature25183
   PubMed Web of Science ®Google Scholar
• Yun KM, Bazhenova LA. Update on lorlatinib: role in reducing the risk of disease progression in ALK-positive NSCLC. Cancer Manag Res. 2022;843–850. doi:10.2147/CMAR.S283199
   PubMed Web of Science ®Google Scholar
• Britschgi C, Addeo A, Rechsteiner M, et al. Real-world treatment patterns and survival outcome in advanced anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer patients. Front Oncol. 2020;10:1299. doi:10.3389/fonc.2020.01299
   PubMed Web of Science ®Google Scholar
• Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1):1–15. doi:10.1186/s12943-018-0810-4
   PubMedGoogle Scholar
• El Darsa H, Abdel-Rahman O, Sangha R. Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer. Expert Opin Pharmacother. 2020;21(13):1547–1554. doi:10.1080/14656566.2020.1774552
   PubMed Web of Science ®Google Scholar
• Choo JR-E, Soo RA. Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. 2020;20(4):233–240. doi:10.1080/14737140.2020.1744438
   PubMed Web of Science ®Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10 R)-7-Amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8, 4-(metheno) pyrazolo [4,3-h][2, 5, 11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–4744. doi:10.1021/jm500261q
   PubMed Web of Science ®Google Scholar
• Page S, Milner-Watts C, Perna M, et al. Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer. 2020;132:187–198. doi:10.1016/j.ejca.2020.03.006
   PubMed Web of Science ®Google Scholar
• Syed YY. Lorlatinib: first global approval. Drugs. 2019;79:93–98. doi:10.1007/s40265-018-1041-0
   PubMed Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–2029. doi:10.1056/NEJMoa2027187
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1667. doi:10.1016/S1470-2045(18)30649-1
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou S-HI. A user’s guide to lorlatinib. Crit Rev Oncol Hematol. 2020;151:102969. doi:10.1016/j.critrevonc.2020.102969
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Bauer TM, Mok TS, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354–366. doi:10.1016/S2213-2600(22)00437-4
   PubMed Web of Science ®Google Scholar
• Reed M, Rosales A-LS, Chioda MD, Parker L, Devgan G, Kettle J. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. Adv Ther. 2020;37:3019–3030. doi:10.1007/s12325-020-01365-3
   PubMed Web of Science ®Google Scholar
• Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019;24(8):1103–1110. doi:10.1634/theoncologist.2018-0380
   PubMed Web of Science ®Google Scholar
• Soo RA, Tan EH, Hayashi H, et al. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: subgroup analysis of a global phase 2 trial. Lung Cancer. 2022;169:67–76. doi:10.1016/j.lungcan.2022.05.012
   PubMed Web of Science ®Google Scholar
• Lu S, Zhou Q, Liu X, et al. Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in People’s Republic of China. J Thorac Oncol. 2022;17(6):816–826. doi:10.1016/j.jtho.2022.02.014
   PubMed Web of Science ®Google Scholar
• Seto T, Hayashi H, Satouchi M, et al. Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study. Cancer Sci. 2020;111(10):3726–3738. doi:10.1111/cas.14576
   PubMed Web of Science ®Google Scholar
• Zhu VW, Lin Y-T, Kim D-W, et al. An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor–refractory ALK-positive or ROS1-positive NSCLC. J Thorac Oncol. 2020;15(9):1484–1496. doi:10.1016/j.jtho.2020.04.019
   PubMed Web of Science ®Google Scholar
• Lee P-H, Chen K-C, Hsu K-H, et al. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients. Anticancer Drugs. 2021;32(10):1099–1104. doi:10.1097/CAD.0000000000001107
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid‐lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–581. doi:10.1016/j.clpt.2006.09.003
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Bauer TM, Ignatius Ou S-H, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non–small-cell lung cancer from the Phase III CROWN Study. J Clin Oncol. 2022;40(31):3593–3602. doi:10.1200/JCO.21.02278
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Abbattista A, Murphy JF, et al. Factors associated with developing neurocognitive adverse events in patients receiving lorlatinib after progression on other targeted therapies. J Thorac Oncol. 2023;18(1):67–78. doi:10.1016/j.jtho.2022.09.219
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599. doi:10.1016/S1470-2045(17)30680-0
   PubMed Web of Science ®Google Scholar
• Jia K, Ren S. Neurocognitive adverse events of lorlatinib: on the way to precise prediction? J Thorac Oncol. 2023;18(1):26–28. doi:10.1016/j.jtho.2022.11.003
   PubMed Web of Science ®Google Scholar
• Topol EJ, Califf RM. Textbook of Cardiovascular Medicine. Lippincott Williams & Wilkins; 2007.
   Google Scholar
• Li J, Pithavala YK, Gong J, LaBadie RR, Mfopou JK, Chen J. The effect of modafinil on the safety and pharmacokinetics of Lorlatinib: a Phase I study in healthy participants. Clin Pharmacokinet. 2021;60:1303–1312. doi:10.1007/s40262-021-01026-w
   PubMed Web of Science ®Google Scholar
• Xtandi E. EPAR—Product Information. European Medicines Agency; 2018.
   Google Scholar
• Xu H, O’Gorman MT, Nepal S, James LP, Ginman K, Pithavala YK. Phase 1 Study evaluating the effects of the proton pump inhibitor rabeprazole and food on the pharmacokinetics of lorlatinib in healthy participants. Clin Pharmacol Drug Dev. 2021;10(11):1395–1404. doi:10.1002/cpdd.1000
   PubMed Web of Science ®Google Scholar
• Riudavets M, Planchard D. An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer. Expert Opin Pharmacother. 2023;24(3):291–299. doi:10.1080/14656566.2022.2161880
   PubMed Web of Science ®Google Scholar
• Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018;8(6):714–729. doi:10.1158/2159-8290.CD-17-1256
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Rooney M, Lin JJ, et al. Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clin Cancer Res. 2019;25(22):6662–6670. doi:10.1158/1078-0432.CCR-19-1436
   PubMed Web of Science ®Google Scholar
• Recondo G, Mezquita L, Facchinetti F, et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clin Cancer Res. 2020;26(1):242–255. doi:10.1158/1078-0432.CCR-19-1104
   PubMed Web of Science ®Google Scholar
• Mizuta H, Okada K, Araki M, et al. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nat Commun. 2021;12(1):1261. doi:10.1038/s41467-021-21396-w
   PubMed Web of Science ®Google Scholar
• Murray BW, Zhai D, Deng W, et al. TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther. 2021;20(9):1499–1507. doi:10.1158/1535-7163.MCT-21-0221
   PubMed Web of Science ®Google Scholar
• Pelish HE, Tangpeerachaikul A, Kohl NE, Porter JR, Shair MD, Horan JC. Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation. Cancer Res. 2021;81(13_Supplement):1468. doi:10.1158/1538-7445.AM2021-1468
   Web of Science ®Google Scholar